Amgen
Search results
4 days ago · CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of ...
2 days ago · Biogen BIIB080 An antisense. Mid-stage trial oligonucleotide. for early-stage therapy. Alzheimer’s directed. against "tau" proteins. Longeveron lomecel-B A cell therapy. Mid-stage trial designed to.
3 days ago · Biogen is known for its neuroscience focus, having co-developed the next-generation Alzheimer’s treatment Leqembi (lecanemab-irmb) with Eisai. The drug is predicted to see US sales of $4.6bn by ...
1 day ago · Biogen’s sales of aducanumab were meager, and the company pulled the antibody from the market earlier this year. Lecanemab secured accelerated approval in January 2023, following in the amyloid ...
2 days ago · Drug or Therapy. Stage of development & indication. Mechanism. Eli Lilly and Co (LLY.N) Kisunla. Secured U.S. FDA's standard approval for early Alzheimer’s. Designed to target and remove toxic ...
5 days ago · After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.
1 day ago · Biogen, a leading biotechnology company that pioneers innovative science to deliver new medicines to patients, has completed the acquisition of Human Immunology Biosciences (HI-Bio). Biogen and HI-Bio, a privately held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs ...
